AMP-activated protein kinase activation suppresses leptin expression independently of adipogenesis in primary murine adipocytes
Biochemical Journal · 2024
DOI: 10.1042/bcj20240003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Journal, 2024. Verfasst von Sophia Bustraan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, U.K. Hauptthemen laut MEDLINE: Adipogenesis, AMP-Activated Protein Kinases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Medical Research Council, UKRI | Biotechnology and Biological Sciences Research Council.
Abstract (Originalsprache)
Adipogenesis, defined as the development of mature adipocytes from stem cell precursors, is vital for the expansion, turnover and health of adipose tissue. Loss of adipogenic potential in adipose stem cells, or impairment of adipogenesis is now recognised as an underlying cause of adipose tissue dysfunction and is associated with metabolic disease. In this study, we sought to determine the role of AMP-activated protein kinase (AMPK), an evolutionarily conserved master regulator of energy homeostasis, in adipogenesis. Primary murine adipose-derived stem cells were treated with a small molecule AMPK activator (BI-9774) during key phases of adipogenesis, to determine the effect of AMPK activation on adipocyte commitment, maturation and function. To determine the contribution of the repression of lipogenesis by AMPK in these processes, we compared the effect of pharmacological inhibition of acetyl-CoA carboxylase (ACC). We show that AMPK activation inhibits adipogenesis in a time- and concentration-dependent manner. Transient AMPK activation during adipogenic commitment leads to a significant, ACC-independent, repression of adipogenic transcription factor expression. Furthermore, we identify a striking, previously unexplored inhibition of leptin gene expression in response to both short-term and chronic AMPK activation irrespective of adipogenesis. These findings reveal that in addition to its effect on adipogenesis, AMPK activation switches off leptin gene expression in primary mouse adipocytes independently of adipogenesis. Our results identify leptin expression as a novel target of AMPK through mechanisms yet to be identified.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, U.K.
- Medical Research Council Laboratory of Medical Sciences, London, U.K.
- Emerging Innovations Unit, Discovery Sciences, R&D, AstraZeneca, Cambridge, U.K.
- Mechanistic and Structural Biology, Biopharmaceuticals R&D, AstraZeneca, Cambridge, U.K.
ORCID-Profile: David Carling, Alice Pollard
Förderung
- Cancer Research UK
- Medical Research Council
- UKRI | Biotechnology and Biological Sciences Research Council
- UKRI | Medical Research Council
Zitieren
APA
Bustraan, S., Bennett, J., Whilding, C., Pennycook, B. R., Smith, D., Barr, A. R., Read, J., Carling, D., & Pollard, A. (2024). AMP-activated protein kinase activation suppresses leptin expression independently of adipogenesis in primary murine adipocytes. Biochemical Journal. https://doi.org/10.1042/bcj20240003
Vancouver
Bustraan S, Bennett J, Whilding C, Pennycook BR, Smith D, Barr AR, et al. AMP-activated protein kinase activation suppresses leptin expression independently of adipogenesis in primary murine adipocytes. Biochemical Journal. 2024. doi:10.1042/bcj20240003
BibTeX
@article{Bustraan2024,
author = {Bustraan, Sophia and Bennett, Jane and Whilding, Chad and Pennycook, Betheney R and Smith, David and Barr, Alexis R and Read, Jon and Carling, David and Pollard, Alice},
title = {AMP-activated protein kinase activation suppresses leptin expression independently of adipogenesis in primary murine adipocytes},
journal = {Biochemical Journal},
year = {2024},
doi = {10.1042/bcj20240003}
}
EUVIMED